Y-Mabs Therapeutics ( (YMAB) ) has released its Q4 earnings. Here is a breakdown of the information Y-Mabs Therapeutics presented to its investors.
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in the development and commercialization of innovative radioimmunotherapy and antibody-based therapeutic products for cancer treatment.
In its latest earnings report, Y-mAbs announced total revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year. The company has also established two business units to enhance the clinical development of its Radiopharmaceuticals Platform and optimize the commercial potential of its DANYELZA product.
Key financial highlights include a 13% increase in total revenues for the fourth quarter compared to the previous year, driven by a rise in license and net product revenues. However, the company faced a decline in U.S. DANYELZA net product revenues due to an unfavorable price mix, while international revenues saw significant growth. Additionally, Y-mAbs reported a net loss of $6.8 million for the quarter, primarily due to increased operating expenses and decreased foreign currency gains.
The company is optimistic about its future growth, with management providing guidance for 2025, expecting total revenues between $75 million and $90 million and operating costs between $116 million and $121 million. Y-mAbs aims to continue its capital-efficient operations with cash and cash equivalents anticipated to fund operations into 2027.
Looking ahead, Y-mAbs remains committed to advancing its clinical and commercial strategies, focusing on expanding the reach of DANYELZA and accelerating the development of its SADA PRIT platform, positioning itself for future growth in the competitive biopharmaceutical landscape.